WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Amarant Groep
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
BioSpace | March 12, 2020
Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...
MEDICAL
Veeva Systems | September 24, 2021
Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...
INDUSTRIAL IMPACT
BioLife Solutions, Inc. | September 06, 2021
BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies. Sexton's bioproduction tools portfolio includes proprietary closed vials for cell therapy final dose packaging, human platelet lysate (HPL) media, a bio-defined replacement for fetal bovine serum or human serum used in cell manuf...
BioNTech SE | February 22, 2022
BioNTech SE and Medigene AG a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. Medigene&rsqu...
CELL AND GENE THERAPY
Whitepaper
MEDTECH
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE
